

Amendment

The following listing of the claims replaces all prior versions and listings of the claims in the application.

Listing of the Claims:

1-37. (Cancelled)

38. (Currently amended) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen fragment comprising an amino acid sequence ~~from any of~~ SEQ ID NOs: 179-356 or fragments thereofencoded by a nucleic acid molecule fragment of SEQ ID NO:110 and comprising amino acids 4-37, 40-46, 52-57, 199-205, 222-229, 236-244, 250-267, 269-282, 27-197, 86-109, and/or 104-127 of SEQ ID NO:288.

39-46. (Cancelled)

47. (Currently amended) The pharmaceutical composition of claim ~~[[45]]~~38, further ~~defined~~ as-comprising at least two different hyperimmune serum-reactive antigens and/or fragments.

48. (Cancelled)

49. (Currently amended) The pharmaceutical composition of claim ~~[[45]]~~38, further comprising an immunostimulatory substance.

50. (Previously Presented) The pharmaceutical composition of claim 49, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

51. (Previously Presented) The pharmaceutical composition of claim 50, wherein the polycationic polymer is a polycationic peptide.

52. (Previously Presented) The pharmaceutical composition of claim 50, wherein the neuroactive compound is human growth hormone.

53. (Currently amended) The pharmaceutical composition of claim ~~[[45]]~~38, ~~further defined as-wherein the composition is a vaccine.~~

54. (Currently amended) The pharmaceutical composition of claim 53, ~~further defined as~~ wherein the vaccine is a vaccine for treatment and/or prevention of *H. pylori* infection.

55. (Withdrawn) A method of vaccinating a subject comprising:

obtaining a pharmaceutical composition of claim 45; and

administering the pharmaceutical composition to a subject;

wherein the subject is vaccinated.

56. (Withdrawn) The method of claim 55, wherein the subject is a human.

57. (Withdrawn) The method of claim 55, wherein the method is a method of treating and/or preventing *H. pylori* infection in the subject.

58. (Withdrawn) The method of claim 55, wherein the hyperimmune serum-reactive antigen or fragment is directed against *H. pylori*.

59. (Withdrawn) The method of claim 55, wherein the pharmaceutical composition comprises at least two different hyperimmune serum-reactive antigens or fragments thereof.

60. (Withdrawn) The method of claim 59, wherein the at least two different hyperimmune serum-reactive antigens or fragments thereof are both directed against *H. pylori*.